• 3^rd generation recombinant immunotoxins (RITs). These fusion proteins connecting a short fragment of an antibody and a truncated form of a toxin are sought for targeted therapies, in oncology (leukemia, solid tumors), against intestinal and pulmonary pathogens, with potential against autoimmune diseases, Parkinson's, amongst other illnesses.

• Antimicrobial (AMPs) and antiviral peptides (AViPs), purified or preferably vectored. They help counteract the increasing resistance of bacteria to antibiotics (AMPs), neutralize the action of viruses through innovative mechanisms (AViPs).

• Antigenic vaccines, vectored in particular for oral and intranasal delivery. The compartmentalization inside the cell brings increased thermostability, a considerable logistical advantage.

Compared to animal cells, yeasts, prokaryotic bacteria and higher plants, the competitive advantages of our system are:

► its ability to produce toxic (or "recalcitrant" molecules)

► excellent product homogeneity (intra- and inter-lot uniformity)

► the possibility of non-parenteral modes of administration

► thermal stabilization, thus a lighter supply chain

In addition, this system will respond very significantly to the challenge of reducing production costs.

It will be further extended to other domains with different molecules: N- and O-glycosylated proteins, monoclonal antibodies, etc.